|Videos|May 6, 2017

Why Healthcare Workers Need to Stay Home When They're Ill

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, stresses the importance of healthcare workers staying home when they’re ill.

Matt Linam, MD, MS, Assistant Professor, Pediatric Infectious Diseases, University of Arkansas for Medical Sciences, stresses the importance of healthcare workers staying home when they’re ill.

Interview Transcript (slightly modified for readability)

“Trying to get healthcare workers to stay home when they’re ill is a big challenge and I think it’s a challenge for all hospitals. There’s this ingrained mentality that ‘we need to work,’ ‘we need to be there,’ there’s staffing challenges that are sometimes very real, and in some cases we’ve actually created a system that penalizes healthcare workers for staying home. So, in order to really try to get healthcare workers to stay home when they’re ill, we really need to be more conscious about the system we’ve created.

Make it very clear when healthcare workers are too ill and when they need to stay home and for some things like fever that’s really cut-and-dried, but for some things like respiratory illness, or respiratory symptoms, it’s not as clear, but when we can make those definitions as clear as possible and create strategies that don’t penalize or create policies that don’t penalize staff for staying home when they’re symptomatic, and help get healthcare workers home when they’re ill, that can help that problem but healthcare workers have been shown to be sources of outbreaks for respiratory viruses, so it’s really important for them to stay home.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.